A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.
暂无分享，去创建一个
E. Plimack | E. Horwitz | R. Uzzo | Philip H. Abbosh | E. Ross | P. Ghatalia | M. Zibelman | D. Geynisman | J. Hoffman-Censits | David Y. T. Chen | R. Alpaugh | A. Kutikov | R. Viterbo | R. Greenberg | L. Stamatakis | M. Smaldone | M. Hallman | J. Mark | Fern Anari | Katherine Ansel